1-9 of 9
Desamparados Roda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Robert Jones, Ruth Plummer, Victor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah Blagden, Alan Anthoney, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 331–340.
https://doi.org/10.1158/1078-0432.CCR-22-2074
Published: 17 January 2023
View article titled, A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer
Open the PDF for A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

Tenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, Thomas Reinert, Francisco Gimeno-Valiente, Juan Antonio Carbonell-Asins, Shruti Sharma, Derrick Renner, Dina Hafez, Desamparados Roda, Marisol Huerta, Susana Roselló, Anders Husted Madsen, Uffe S. Løve, Per Vadgaard Andersen, Ole Thorlacius-Ussing, Lene Hjerrild Iversen, Kåre Andersson Gotschalck, Himanshu Sethi, Alexey Aleshin, Andres Cervantes, Claus Lindbjerg Andersen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 507–517.
https://doi.org/10.1158/1078-0432.CCR-21-2404
Published: 01 February 2022
View article titled, Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
Open the PDF for Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences in another window
Includes: Supplementary data
Journal Articles

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer

Valentina Gambardella, Francisco Gimeno-Valiente, Noelia Tarazona, Carolina Martinez Ciarpaglini, Desamparados Roda, Tania Fleitas, Pablo Tolosa, Juan Miguel Cejalvo, Marisol Huerta, Susana Roselló, Josefa Castillo, Andrés Cervantes
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (5): 1639–1649.
https://doi.org/10.1158/1078-0432.CCR-18-2421
Published: 01 March 2019
View article titled, NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in <em>HER2</em>-Amplified Gastric Cancer
Open the PDF for NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in <em>HER2</em>-Amplified Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?

Desamparados Roda, Begoña Jimenez, Udai Banerji
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (9): 2127–2132.
https://doi.org/10.1158/1078-0432.CCR-15-1855
Published: 01 May 2016
View article titled, Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
Open the PDF for Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic? in another window
Includes: Supplementary data
Journal Articles

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Dejan Juric, Rodrigo Dienstmann, Andres Cervantes, Manuel Hidalgo, Wells Messersmith, George R. Blumenschein, Jr, Josep Tabernero, Desamparados Roda, Antonio Calles, Antonio Jimeno, Xiaodong Wang, Sandra Sanabria Bohórquez, Cecilia Leddy, Catherine Littman, Amy V. Kapp, David S. Shames, Elicia Penuel, Lukas C. Amler, Andrea Pirzkall, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (11): 2462–2470.
https://doi.org/10.1158/1078-0432.CCR-14-2412
Published: 31 May 2015
View article titled, Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
Open the PDF for Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors in another window
Journal Articles

Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Saeed Rafii, Desamparados Roda, Elena Geuna, Begona Jimenez, Karim Rihawi, Marta Capelan, Timothy A. Yap, L. Rhoda Molife, Stanley B. Kaye, Johann S. de Bono, Udai Banerji
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (8): 1869–1876.
https://doi.org/10.1158/1078-0432.CCR-14-2424
Published: 14 April 2015
View article titled, Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials
Open the PDF for Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

Serena Di Cosimo, Sriram Sathyanarayanan, Johanna C. Bendell, Andrés Cervantes, Mark N. Stein, Irene Braña, Desamparados Roda, Brian B. Haines, Theresa Zhang, Christopher G. Winter, Sharda Jha, Youyuan Xu, Jason Frazier, Richard A. Klinghoffer, Ann Leighton-Swayze, Yang Song, Scot Ebbinghaus, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 49–59.
https://doi.org/10.1158/1078-0432.CCR-14-0940
Published: 05 January 2015
View article titled, Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Open the PDF for Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodríguez, Marta Guzman, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao, Marie-Claire Wagle, Jenny Q. Wu, Matthew Wongchenko, Garret Hampton, Vanitha Ramakrishnan, Mark R. Lackner, Cristina Saura, Desamparados Roda, Andrés Cervantes, Josep Tabernero, Premal Patel, José Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (24): 6976–6986.
https://doi.org/10.1158/1078-0432.CCR-13-0978
Published: 16 December 2013
View article titled, Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
Open the PDF for Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068 in another window
Includes: Supplementary data
Journal Articles

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

Andres Cervantes, Elena Elez, Desamparados Roda, Jeffrey Ecsedy, Teresa Macarulla, Karthik Venkatakrishnan, Susana Roselló, Jordi Andreu, JungAh Jung, Juan Manuel Sanchis-Garcia, Adelaida Piera, Inma Blasco, Laura Maños, José-Alejandro Pérez-Fidalgo, Howard Fingert, Jose Baselga, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4764–4774.
https://doi.org/10.1158/1078-0432.CCR-12-0571
Published: 30 August 2012
View article titled, Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data